NZ744112B2 - Treatments and prevention of opioid neonatal abstinence syndrome - Google Patents
Treatments and prevention of opioid neonatal abstinence syndromeInfo
- Publication number
- NZ744112B2 NZ744112B2 NZ744112A NZ74411217A NZ744112B2 NZ 744112 B2 NZ744112 B2 NZ 744112B2 NZ 744112 A NZ744112 A NZ 744112A NZ 74411217 A NZ74411217 A NZ 74411217A NZ 744112 B2 NZ744112 B2 NZ 744112B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- opioid
- antagonist
- opioid antagonist
- subject
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Abstract
Disclosed is a method for reducing or preventing fetal opioid dependence in a drug dependent or opioid tolerant pregnant subject. The method involves administering to the pregnant subject a composition comprising an opioid antagonist in an amount effective to reduce or prevent fetal opioid dependence, wherein the opioid antagonist a) is orally available or delivered systemically and reaches the circulation of the pregnant subject, b) is substantially excluded from the subject's brain by the blood brain barrier, and c) penetrates the placenta and enters the fetal brain. The method also includes administering the opioid antagonist to the neonate in increasing amounts to facilitate weaning the neonate from continued opioid maintenance.
Claims (21)
1. Use of an opioid antagonist in the manufacture of a medicament for reduction or prevention of opioid dependence of a fetus carried by a drug dependent or opioid tolerant pregnant subject receiving opioid therapy or maintenance, wherein the opioid antagonist is a neutral antagonist to a µ-opioid receptor.
2. The use of claim 1, wherein the opioid antagonist comprises 6ß-naltrexol.
3. The use of claim 1 or claim 2, wherein the opioid antagonist is delivered in two daily subdoses.
4. The use of any one of claims 1 to 3, wherein the opioid antagonist is delivered in a daily dosage range from about 0.1 mg to about 100 mg.
5. The use of any one of claims 1 to 4, wherein the medicament comprises a sustained drug release formulation.
6. The use of any one of claims 1 to 5, wherein the opioid antagonist is orally available.
7. The use of any one of claims 1 to 6, wherein the reduction or prevention further comprises administration of a palliative therapy.
8. The use of any one of claims 1 to 7, wherein the reduction or prevention further comprises administration of a 5-HT antagonist.
9. The use of claim 8, wherein the 5HT antagonist is ondansetron.
10. Use of an opioid antagonist in the manufacture of a medicament for the treatment of neonatal withdrawal or abstinence syndrome in an infant subject.
11. The use of claim 10, wherein the opioid antagonist comprises 6ß-naltrexol.
12. The use of claim 10 or claim 11, wherein the opioid antagonist is a neutral antagonist and not an inverse agonist.
13. The use of any one of claims 10 to 12, wherein the opioid antagonist does not comprise naloxone or naltrexone.
14. The use of any one of claims 10 to 13, wherein the opioid antagonist is delivered in two daily subdoses.
15. The use of any one of claims 10 to 14, wherein the opioid antagonist is delivered in a daily dosage range from about 0.1 mg to about 100 mg.
16. The use of any one of claims 10 to 15, wherein the opioid antagonist is comprised in a sustained drug release formulation.
17. The use of any one of claims 10 to 16, wherein the opioid antagonist is orally available.
18. The use of any one of claims 10 to 17, wherein the treatment further comprises administration of a palliative therapy to a pregnant subject and/or the infant subject.
19. The use of any one of claims 10 to 18, wherein the treatment further comprises administration of a 5-HT antagonist to a pregnant subject and/or the infant subject.
20. The use of claim 19, wherein the 5-HT antagonist is ondansetron.
21. Use of any one of claims 1 to 20, substantially as herein described with reference to any example thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276691P | 2016-01-08 | 2016-01-08 | |
| PCT/US2017/012452 WO2017120417A1 (en) | 2016-01-08 | 2017-01-06 | Treatments and prevention of opioid neonatal abstinence syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ744112A NZ744112A (en) | 2025-05-30 |
| NZ744112B2 true NZ744112B2 (en) | 2025-09-02 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240261278A1 (en) | Abuse-resistant mucoadhesive devices for delivery of buprenorphine | |
| AU2013305563B2 (en) | Chemical compositions and methods for enhancing transdermal delivery of therapeutic agents | |
| Ko | Neuraxial opioid-induced itch and its pharmacological antagonism | |
| CA2661759A1 (en) | Buprenophine-wafer for drug substitution therapy | |
| CN111479592B (en) | Treatment of Opioid Use Disorder, Opioid Withdrawal Symptoms, and Chronic Pain | |
| CA2723685C (en) | Oral administration of peripherally-acting opioid antagonists | |
| NO20170380A1 (en) | Transmucosal delivery device with increased uptake | |
| NZ784949A (en) | Ripretinib for treating gastrointestinal stromal tumors | |
| JP2019501194A5 (en) | ||
| CA3010609A1 (en) | Treatments and prevention of opioid neonatal abstinence syndrome | |
| JP2016520114A5 (en) | ||
| MX2015009546A (en) | Increased dosage of efavirenz for the treatment of cancer. | |
| Sturn et al. | Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients | |
| TN2019000063A1 (en) | Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof | |
| NZ744112B2 (en) | Treatments and prevention of opioid neonatal abstinence syndrome | |
| Lee et al. | The effect of transdermal scopolamine plus intravenous dexamethasone for the prevention of postoperative nausea and vomiting in patients with epidural PCA after major orthopedic surgery | |
| US20190209540A1 (en) | Sublingual opioid formulations containing naloxone | |
| IL312328A (en) | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance | |
| EP2560646B1 (en) | Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain | |
| Kotila et al. | Steroid induced diabetes mellitus in patients receiving prednisolone for haematological disorders | |
| WO2016193454A3 (en) | Dosage of naloxone | |
| Kopecky et al. | (445) Efficacy and safety of oxycodone DETERx: results of a randomized, double-blind, placebo-controlled phase III study | |
| WO2016193456A3 (en) | Opioid receptor antagonist for use in treating patients with severe constipation | |
| US20120283283A1 (en) | Methods for detecting enhanced risk of opioid-induced hypoxia in a patient | |
| Bichai | Pharmacokinetics and residues of Oxytetracycline hydrochloridein hybrid tilapia (Oreochromis aureus× O. niloticus) |